Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
vendredi, octobre 02
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Foghorn Therapeutics Inc
FHTX
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$2.92
-0.65
-18.21%
Dern. MÀJ: Oct 1, 7:59 PM
$2.89
-0.68
-19.05%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
PRO
Pourquoi cela bouge-t-il ?:
Foghorn Therapeutics shares are trading lower after the company and Lilly d...
Foghorn Therapeutics Financials
Foghorn Therapeutics (FHTX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Foghorn Therapeutics Q2 EPS $(0.10) Beats $(0.23) Estimate, Sales $16.072M Beat $5.995M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.23) by 54.55 percent. This is a 64.29 percent increase over losses of $(0.28) per share
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q1 EPS $(0.29), Inline, Sales $3.267M Miss $7.438M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.29) per share which met the analyst consensus estimate. This is a 3.33 percent increase over losses of $(0.30) per share from the same period last year.
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q4 EPS $(0.34) Misses $(0.27) Estimate, Sales $9.247M Miss $9.500M Estimate
.
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q3 EPS $(0.25) Beats $(0.30) Estimate, Sales $8.153M Beat $6.197M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 17.76 percent. This is a 19.35 percent increase over losses of $(0.31) per share
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q2 EPS $(0.28) Beats $(0.33) Estimate, Sales $7.557M Beat $6.498M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.33) by 13.85 percent. This is a 37.78 percent increase over losses of $(0.45) per share
Benzinga Newsdesk
PRO
Foghorn Therapeutics Q1 EPS $(0.30) Beats $(0.31) Estimate, Sales $5.95M Beat $5.82M Estimate
Foghorn Therapeutics (NASDAQ:FHTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.31) by 3.23 percent. This is a 49.15 percent increase over losses of $(0.59) per share
Benzinga Newsdesk
